Non-SMEs to benefit from greater orphan drug fee relief in EU
This article was originally published in SRA
Larger companies are to benefit from more fee reductions and exemptions for orphan drug services after the European Medicines Agency broadened its fee reduction policy for sponsors that are not micro, small or medium-sized enterprises (SMEs)1.
You may also be interested in...
At current rates, not enough coronavirus vaccines will be manufactured in 2021 or even 2022 to meet global demand or achieve global population immunity, according to a new dataset that monitors vaccine supply agreements around the world.
Coronavirus Notebook: Africa Backs IP Waiver Proposal, CEOs To Face EU Parliamentary Hearing On Vaccine Supply
Sanofi and GSK have restarted their Phase II vaccine study, Australia is allowing public advertising of coronavirus vaccines, and Sputnik V has landed in Mexico.
After a few false starts, it seems that the EU regulator has begun preparing the ground for a review of Russia’s adenovirus-based COVID-19 vaccine.